BACKGROUND: Clinical practice recommendations from American Diabetes Association (ADA) include specific prevention goals intended to reduce the risk of diabetic complications. The Healthy People 2010 (HP2010) initiative, updated to Healthy People 2020, proposes similar objectives for improvement of clinical measures and outcomes in patients with diabetes. Clinical pharmacists are gaining an increasing role in providing diabetes management services, including collaborative practice in medical groups.
B R I E F C O M M U N I C AT I O N
T he published literature shows that when pharmacists are added to the health care team in providing diabetes management, an improvement in glycosylated hemoglobin (A1c) can be seen. [1] [2] [3] [4] Additional targets for diabetes care, such as normalization of blood pressure and reduction in 10-year risk for cardiovascular events according to Framingham risk scores, have also been achieved in studies of pharmacist interventions. [1] [2] [3] 5, 6 The effects of clinical pharmacist interventions in attainment of preventive goals in diabetes have not been assessed. The standards of medical care in diabetes from the American Diabetes Association (ADA) suggest specific preventive goals to reduce the risk of or slow the progression of complications related to diabetes, including nephropathy, retinopathy, and cardiovascular disease. 7, 8 The 2009 ADA standards of medical care in diabetes proposed the following goals to prevent diabetes-related complications: annual eye and foot exams, annual screening for the presence of urinary microalbumin, low-density lipoprotein cholesterol (LDL-C) < 100 milligrams per deciliter (mg per dL), blood pressure < 130/80 millimeters mercury (mm Hg), and daily aspirin therapy. 7 The 2010 and 2011 updates to the ADA standards of medical care in diabetes narrowed the recommended use of aspirin to persons with increased cardiovascular risk, defined as most men aged over 50 years and women aged over 60 years who have at least 1 additional major cardiovascular risk factor (e.g., family history of cardiovascular disease, hypertension, smoking, hyperlipidemia, or albuminuria). 9, 10 The ADA and Centers for Disease Control and Prevention also recommend an annual influenza vaccination for all patients 6 months of age or older and at least 1 lifetime pneumococcal vaccine for patients with diabetes who are at least 2 years of age. 10, 11 The Healthy People 2010 (HP2010) initiative proposed clinical practice recommendations similar to the recommendations issued by the ADA (2009 and 2010). 7, 9, 12 HP2010 is a national initiative managed by the Office of Disease Prevention and Health Promotion and the U.S. Department of Health and Human Services. The initiative was developed to help increase life expectancy, improve quality of life, and eliminate health disparities of individuals in the United States.
12 HP2010, superseded by HP2020, 13 includes specific health objectives
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■■ Methods Setting
This study was a retrospective review of electronic medical records (EMRs) to assess whether there was a difference in goal achievement for diabetes management for patients enrolled in a pharmacist-managed diabetes clinic versus usual physician care in a primary care medical practice. The primary care clinic provides services to Medicare, managed care, and fee-for-service patients within a multispecialty physician group practice located in the Midwest region. The organization is composed of more than 140 physicians and 600 full-time and 400 part-time support staff who provide care at 11 service locations in a suburban metropolitan area in Illinois. Usual care for patients with diabetes includes the provision of preventive care services and screenings; medication management; education of the patient in 28 different areas of health care, including diabetes and diabetes-related comorbidities. Selected diabetes-specific and diabetes-related HP2010 objectives are shown in Figure 1 . Health care professionals serve as important intermediaries to assist patients in accomplishing the ADA and HP2010-2020 preventive care measures. Clinical pharmacists are gaining an increasing role in providing patient care services, specifically in diabetes management. [14] [15] [16] The purpose of this study was to compare the rates of treatment goal achievement for patients receiving clinical pharmacist interventions with patients receiving usual physician care, based on prevention goals described by the ADA clinical practice recommendations and the HP2010 initiative for patients with diabetes mellitus (Figure 2 ). by the primary care physician (PCP), nurse practitioners or physician assistants working under the supervision of the PCP, or nursing staff working directly with the PCP; and referral to other physician specialists (e.g., endocrinology) if deemed appropriate by the PCP.
Description of the Intervention
Through a collaborative practice agreement, 3 university-affiliated pharmacists educate and directly manage drug therapy and preventive care services for patients diagnosed with diabetes mellitus. Patients can be referred to the pharmacistmanaged diabetes clinic by either physician referral or through an automatic referral process. The automatic referral process allows the pharmacists, via protocol and without a physician referral, to enroll patients into the diabetes clinic who have an A1c of 9% or higher. There are no formal criteria for physician referral to the pharmacist-managed diabetes clinic, and the physician referrals come from across the continuum-of-care for patients with diabetes (i.e., including those with new diagnoses, long-standing diabetes, and those with controlled to severely uncontrolled diabetes). Reasons for physician referral vary depending on assessments of patients and include those who require medication titration or reconciliation, initiation of insulin, and diabetes education to those needing close monitoring and follow-up. Pharmacists manage these patients per protocol that emphasizes the ADA guidelines. Pharmacists have autonomy in assessing patients, providing disease-state education, reviewing current medication lists, initiating or adjusting medication therapy, ordering laboratory tests, and determining appropriate follow-up. Pharmacists meet with new patients for approximately 45 minutes at the initial visit and returning patients for approximately 30 minutes per visit.
Sample Selection
For the purposes of this study, a convenience sample of 321 patients with diabetes managed by PCPs (usual care group) were compared with 321 patients enrolled in a pharmacist-managed diabetes clinic (intervention group) between January 1, 2007, and December 31, 2007. Cases in the intervention and usual care groups were pulled from a sample of 7,068 total patients (1,298 intervention and 5,770 usual care, Figure 3) . A Crystal Reports database query identified 24,768 encounters that had at least 1 diabetes diagnosis code (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] code range 250.00-250.99) during the 12 months in calendar year 2007 in the primary care departments (internal medicine or family practice). The 7,068 unique patients were divided into those who had previous visits with the pharmacist-managed diabetes clinic (1, 298) and those who had no history of visits (5,770) with the pharmacist-managed diabetes clinic.
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FIGURE 2
Preventive Care Measures in the Present Study
Healthy People 2010 12 Proportion of patients receiving an A1c in the 6 months preceding data collection Of the 1,298 patients with previous visits with the pharmacist-managed diabetes clinic, only 321 patients (150 male, 171 female) were aged 18 years or older and had 2 or more visits within the pharmacist-managed diabetes clinic during the study period. This intervention group was compared with 321 patients who were randomly selected after gender stratification from among 3,022 diabetes patients who had at least 2 medical encounters with a PCP and no interaction with the pharmacistmanaged diabetes clinic in 2007.
The data for general demographics; laboratory values/dates; visit dates (office visits, education visits, dietician visits); vital signs such as blood pressure, vaccinations, medications, eye, and foot examinations; and smoking status/counseling were extracted using Crystal Reports database queries. Other information such as race, physical activity, dentistry visits, and self-monitored blood glucose (SMBG) frequency were extracted through manual chart review of all clinic encounters with dates of service during calendar year 2007. The extracted data were entered manually into a Microsoft Access 2003 Database (Microsoft Inc., Redmond, WA). The manual chart review and manual data entry were completed by a doctor of pharmacy candidate; all Crystal Reports database queries and Microsoft Access 2003 data manipulations were performed by one of the authors (Rihani).
Descriptive statistics and chi-square analysis were used to analyze the results of this study. This study was approved by the Midwestern University Institutional Review Board.
■■ Results
Six hundred forty-two medical records were reviewed in this study (n = 321 for each group). The majority of patients had type 2 diabetes (n = 310 [96.6%] in usual care and n = 302 [94.1%] in the intervention group), and more than 60% were Caucasian in both groups (n = 199 in usual care and n = 219 in the intervention group, Table 1 ).
The review of the ADA clinical measures identified 269 patients in the intervention group and 256 patients in the usual care group who had a diagnosis of hypertension. Of these, 44.6% (n = 120/269) in the intervention group and 48.0% (n = 123/256) in the usual care group were at goal blood pressure at the most recent measurement (P = 0.430). LDL-C goal was achieved in 76.0% of patients in the intervention group (n = 244/321) versus 59.2% (n = 190/321) in the usual care group (P < 0.001, Table 2 ).
The intervention group achieved 9 of the 14 HP2010 objectives (12 objectives in Table 2 and 2 vaccination objectives in Table 3 ) measured in the present study, compared with 7 of 14 objectives achieved in the usual care group. Neither the usual care group nor the intervention group achieved the influenza and pneumococcal vaccination objectives, but the proportion of patients with vaccinations was higher for the intervention group in 3 of the 4 comparisons by age ( Table 3 ). The intervention group had higher proportions of patients with goal achievement in formal diabetes education, annual urinary Table 2 ). The usual care group had a higher proportion of patients with A1c < 7% (71.0% vs. 50.8%, P < 0.001) and a lower proportion with no leisure time physical activity (19.3% vs. 38.6%, P < 0.001). The usual care group failed to achieve the target goals for formal education, annual eye and foot exam, annual dietician visit, and total smoker goals; smoking cessation counseling was provided to more than 75% of smokers in both the usual care (77.8%, n = 35/45) and intervention groups (76.7%, n = 23/30). Some initiatives or goals, such as documentation of dental exams, were not measurable or easily retrievable through data queries or medical chart review and thus were modified or omitted from the study. With regard to the HP2010 objective for chronic kidney disease, both the intervention and usual care groups far exceeded the 30% target for use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) in patients with proteinuria, and there was no difference between the intervention group and usual care. Neither group met the 75% target for dietician visits in the past year, but the intervention group had a higher proportion of patients who had a visit with a dietician (48.9% vs. 7.5%, P < 0.001). random assignment to the intervention and usual care groups prevented attribution of causality. Third, at the time this study was conducted, patient data were retrospectively collected from 2007 and analyzed using the 2009 ADA recommendations. The ADA guidelines for aspirin therapy changed in 2010 in which aspirin is no longer recommended in every diabetes patient over 40 years of age. 10 Additionally, this study compares results with goals from the HP2010 initiative, which was superseded by HP2020 that includes other new and modified objectives for diabetes, such as improving glycemic control, blood pressure, and lipids among the population diagnosed with diabetes, as well as increasing the proportion of people at risk for diabetes who are engaged in behaviors to prevent diabetes. Objectives that were retained from HP2010, but modified include reducing the annual number of new cases of diagnosed diabetes and reducing the death rate among those with diabetes.
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FIGURE 3
Derivation of Patient Samples in Usual Care and Intervention Groups
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Fourth, lack of complete and/or adequate documentation in the EMRs was a limitation in terms of the statistical analysis. For example, evaluation of services such as eye exams and dental exams are only included in the medical record if the treating ophthalmologist, optometrist, or dentist copies the PCP on their documentation. It is not standard practice for dentists and optometrists to report patient visits back to the medical center. Fifth, both physical activity and smoking cessation attempts were self-reported and therefore may not be reliable. Sixth, this study examined patient data from mostly elderly Caucasians who have health insurance; therefore, this group may not be representative of patients in other settings.
■■ Conclusions
Adults with diabetes who had at least 2 visits to the pharmacist-managed diabetes clinic in 2007 attained 9 of 14 Healthy People 2010 objectives compared with 7 of 14 objectives attained by patients in usual care managed by PCPs and other clinicians without clinical pharmacist involvement. The absence of baseline values for A1c, blood pressure, and LDL-C prevented longitudinal assessment of the effects of this clinical pharmacist intervention.
■■ Discussion
Clinical pharmacists are gaining increasing roles in the management of diabetes. [14] [15] [16] The results of the present study support the role of the pharmacist in helping diabetes patients meet the ADA (2009) and HP2010-2020 preventive care objectives. Pharmacists in collaborative practice in diabetes management in medical groups may support primary care physicians and other clinicians in meeting preventive care objectives. The results of the present study have been used by this medical group to help validate the value of pharmacists in the delivery of care to patients with diabetes and as a model for the management of other chronic diseases. The organization uses these results to help promote the value of the pharmacist-managed diabetes clinic to PCPs. In addition, many of the HP2010 objectives evaluated in this study are core measures of pay-for-performance programs in which the medical group participates. The role of pharmacist involvement in diabetes management is further solidified by these results as they directly impact organizational goal attainment for these pay-for-performance measures. Lastly, the results of this study have helped highlight the need for processes to assist PCPs in identifying which preventive care services are needed for a given patient. Thus, pharmacists can assist physicians and other clinicians in helping patients achieve diabetes preventive measures, which may ultimately decrease complications, reduce costs, and increase quality of life.
Although the proportion of patients achieving the target for average A1c was higher in the usual care group and leisuretime physical activity was more common among patients in the usual care group, physicians in this medical group often refer patients who are uncontrolled and need significant improvement to the pharmacist-managed diabetes clinic. Pharmacists may also enroll patients in the pharmacist-managed diabetes clinic under protocol, without specific physician referral, when A1c is 9% or greater.
Limitations
The foremost limitation of this study was the inability to assess clinical care improvement because of the absence of baseline values. Second, our use of an observational design without 
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